ASPE
Aspen Neuroscience, Inc. (ASPE)
Healthcare • NASDAQ • $12.23-2.86%
- Symbol
- ASPE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $12.23
- Daily Change
- -2.86%
- Market Cap
- $366.10M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $14.90
- 52W Low
- $11.20
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- N/A
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.
Company websiteResearch ASPE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.